We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Snibe Diagnostic’s Maglumi SARS-CoV-2 S-RBD IgG Test Receives CE Mark

By HospiMedica International staff writers
Posted on 05 Aug 2020
Snibe Diagnostic (Shenzhen, China) has received the CE mark for its fully automated quantitative serology test for detecting IgG antibodies against SARS-CoV-2S-RBD, the receptor-binding domain of S protein.

The test, called Maglumi SARS-CoV-2 S-RBD IgG, is designed for the quantitative detection of antibodies to the receptor-binding domain of the S protein, which are believed to neutralize the coronavirus and are an effective measure of immunity as compared to antibodies that target other SARS-CoV-2 proteins. More...
According to Snibe, the test has 99.6% specificity and 100% sensitivity at 15 days following the onset of symptoms for COVID-19, thus providing more accurate results. A strong correlation to neutralizing antibodies ensures better clinical management.

The test can be run on the company’s Maglumi CLIA systems, including the Maglumi X8 immunoassay analyzer which can run up to 600 tests per hour. More than 13,000 Maglumi CLIA system installations across the world pave the way for wide availability of the test. Snibe has confirmed that it is ready to ship the Maglumi SARS-CoV-2 S-RBD IgG test worldwide.

Related Links:
Snibe Diagnostic


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
New
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.